Drug Approval | March 01, 2022
Lupin launches Sevelamer Hydrochloride tablets in the United States
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Dr. Raman has succeeded Victoria Richon
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Subscribe To Our Newsletter & Stay Updated
